Open AccessLow Risk of Anti-Human Leukocyte Antigen Antibody Sensitization After Combined Kidney and Islet Transplantation
Author(s) -
Sylvie FerrariLacraz,
Thierry Berney,
Philippe Morel,
Nicola Marangon,
Karine Hadaya,
Sandrine Demuylder-Mischler,
Georg Pongratz,
Nadine Pernin,
Jean Villard
Publication year - 2008
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e31817ba628
Subject(s) - islet , transplantation , medicine , kidney transplantation , sensitization , immunology , human leukocyte antigen , kidney , antibody , immunization , antigen , insulin
Anti-human leukocyte antigen (HLA) antibody could lead to humoral rejection and a decrease in graft survival after kidney transplantation. A recent report has suggested that islet transplantation alone is associated with a high rate of sensitization. The withdrawal of the immunosuppressive therapy because of the progressive nonfunction of the islets could explain the high rate of sensitization. Because the specific risk of immunization of multiple islet infusions remains unknown, we studied the immunization rate in our cohort of multiple islet infusions transplant recipients. De novo anti-HLA antibodies were analyzed in 37 patients after islets alone (n=8), islet-after-kidney (n=13), and simultaneous islet-kidney (n=16) transplantation by solid phase assays over time. The rate of immunization was 10.8% that is comparable with the risk of immunization after kidney transplantation alone. Multiple islet infusions do not represent a specific risk for the development of anti-HLA antibodies after combined kidney-islets transplantation.